AKT1 and neoplasm: AMG 888 was reported to block ErbB-induced AKT and ERK signaling and to inhibit in vitro and in vivo growth of multiple tumor cell lines as single agent or, even better in combination with other ErbB family inhibitors, such as cetuximab.